{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T05:47:18Z","timestamp":1793771238916,"version":"4.6.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T00:00:00Z","timestamp":1710288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T00:00:00Z","timestamp":1710288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100022089","name":"University of Botswana","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100022089","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Vitamin K antagonists (VKA) is the primary anticoagulant in most settings of Sub-Saharan Africa. Understanding the quality of anticoagulation services in the continent is vital in optimising the intended benefits. This study assessed the quality of anticoagulation and associated factors among VKA-treated patients in nine SSA countries. We conducted a retrospective cohort study of randomly selected patients on anticoagulation from 20 clinics in Botswana, the Democratic Republic of Congo, Ethiopia, Gambia, Ghana, Mozambique, Nigeria, Tanzania, and South Africa. Eligible participants were those on VKAs for at least three months and with at least four international normalised ratios (INR) results in 2019\u20132021. We report the proportion of INR values in the therapeutic range, time-in-therapeutic range (TTR) using the Rosendaal method, and the proportion of patients with TTR\u2009\u2265\u200965% (optimal anticoagulation). The mean age was 51.1(16.1) years, and 64.2% were women. The most common indications for VKA included venous thromboembolism (29.6%), prosthetic valves (26.7%) and atrial fibrillation\/flutter (30.1%). We analysed 6743 INR tests from 1011 participants, and of these, 48.5% were sub-therapeutic, 34.1% therapeutic, and 17.4% were supratherapeutic relative to disease-specific reference ranges. TTR was calculated for 660 patients using 4927 INR measurements. The median (interquartile range [IQR]) TTR was 35.8(15.9,57.2) %. Optimal anticoagulation control was evident in 19.2% of participants, varying from 2.7% in Tanzania to 23.1% in Ethiopia. The proportion of patients with TTR\u2009\u2265\u200965% was 15,4% for prosthetic heart valves, 21.1% for venous thromboembolism and 23.7% for atrial fibrillation or flutter. Countries with universal health coverage had higher odds of optimal anticoagulation control (adjusted odds ratio (aOR) 1.79, 95% confidence interval [CI], 1.15\u2013 2.81, p\u2009=\u20090.01). Patients on VKAs for different therapeutic indications in SSA had suboptimal TTR. Universal health coverage increased the odds of achieving TTR by 79%. The evidence calls for more intensive warfarin management strategies in SSA, including providing VKA services without out-of-pocket payments.<\/jats:p>","DOI":"10.1007\/s11239-023-02928-1","type":"journal-article","created":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T04:32:07Z","timestamp":1710304327000},"page":"613-621","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Anticoagulation control among patients on vitamin K antagonists in nine countries in Sub-Saharan Africa"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5947-3684","authenticated-orcid":false,"given":"Julius Chacha","family":"Mwita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel Msafiri","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chriselda","family":"Pillay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Okechukwu S.","family":"Ogah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dejuma Yadeta","family":"Goshu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Agyekum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Mukuka","family":"Musonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maduka Chiedozie","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Endale","family":"Tefera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsie","family":"Kabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keolebile Irene","family":"Ditlhabolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kagiso","family":"Ndlovu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayoola Yekeen","family":"Ayodele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wigilya P.","family":"Mikomangwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilly","family":"Chillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albertino","family":"Damasceno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aba Ankomaba","family":"Folson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Oyekunle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erius","family":"Tebuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrick","family":"Kalokola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Forrest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamilu","family":"Karaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fina Lubaki","family":"Jean-Pierre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chala Fekadu","family":"Oljira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamrat","family":"Assefa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tolulope Shogade","family":"Taiwo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chibuike E.","family":"Nwafor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olufemi","family":"Omole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Anakwue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,13]]},"reference":[{"issue":"6","key":"2928_CR1","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1111\/j.1365-2141.2008.07119.x","volume":"141","author":"D Wardrop","year":"2008","unstructured":"Wardrop D, Keeling D (2008) The story of the discovery of heparin and warfarin. Br J Haematol 141(6):757\u2013763. https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07119.x","journal-title":"Br J Haematol"},{"issue":"11","key":"2928_CR2","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1056\/NEJMoa2209051","volume":"387","author":"SJ Connolly","year":"2022","unstructured":"Connolly SJ, Karthikeyan G, Ntsekhe M et al (2022) Rivaroxaban in rheumatic heart disease-associated atrial fibrillation. N Engl J Med 387(11):978\u2013988. https:\/\/doi.org\/10.1056\/NEJMoa2209051","journal-title":"N Engl J Med"},{"issue":"6","key":"2928_CR3","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1160\/th13-06-0443","volume":"110","author":"R De Caterina","year":"2013","unstructured":"De Caterina R, Husted S, Wallentin L et al (2013) Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost 110(6):1087\u20131107. https:\/\/doi.org\/10.1160\/th13-06-0443","journal-title":"Thromb Haemost"},{"issue":"3","key":"2928_CR4","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1378\/chest.126.3_suppl.204S","volume":"126","author":"J Ansell","year":"2004","unstructured":"Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E (2004) The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(3):204\u2013233. https:\/\/doi.org\/10.1378\/chest.126.3_suppl.204S","journal-title":"Chest"},{"issue":"1","key":"2928_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11239-007-0106-9","volume":"25","author":"S Kaatz","year":"2008","unstructured":"Kaatz S (2008) Determinants and measures of quality in oral anticoagulation therapy. J Thromb Thrombolysis 25(1):61\u201366. https:\/\/doi.org\/10.1007\/s11239-007-0106-9","journal-title":"J Thromb Thrombolysis"},{"issue":"9","key":"2928_CR6","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1016\/s0735-1097(03)00416-9","volume":"41","author":"J Hirsh","year":"2003","unstructured":"Hirsh J, Fuster V, Ansell J, Halperin JL (2003) American Heart Association\/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol 41(9):1633\u20131652. https:\/\/doi.org\/10.1016\/s0735-1097(03)00416-9","journal-title":"J Am Coll Cardiol"},{"issue":"2 Suppl","key":"2928_CR7","doi-asserted-by":"publisher","first-page":"5s","DOI":"10.1378\/chest.95.2_Supplement.5S","volume":"95","author":"J Hirsh","year":"1989","unstructured":"Hirsh J, Poller L, Deykin D, Levine M, Dalen JE (1989) Optimal therapeutic range for oral anticoagulants. Chest 95(2 Suppl):5s\u201311s. https:\/\/doi.org\/10.1378\/chest.95.2_Supplement.5S","journal-title":"Chest"},{"issue":"3","key":"2928_CR8","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1055\/s-0038-1651587","volume":"69","author":"FR Rosendaal","year":"1993","unstructured":"Rosendaal FR, Cannegieter SC, van der Meer FJ, Bri\u00ebt E (1993) A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 69(3):236\u2013239","journal-title":"Thromb Haemost"},{"key":"2928_CR9","unstructured":"National Institute for Health and Care Excellence Atrial fibrillation: diagnosis and management (Clinical guideline196). 2021. https:\/\/www.nice.org.uk\/guidance\/ng196\/chapter\/Recommendations#stroke-prevention."},{"issue":"5","key":"2928_CR10","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2020","unstructured":"Hindricks G, Potpara T, Dagres N et al (2020) 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 42(5):373\u2013498. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa612","journal-title":"Eur Heart J"},{"issue":"5","key":"2928_CR11","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1378\/chest.129.5.1155","volume":"129","author":"C van Walraven","year":"2006","unstructured":"van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ (2006) Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest 129(5):1155\u20131166. https:\/\/doi.org\/10.1378\/chest.129.5.1155","journal-title":"Chest"},{"issue":"2","key":"2928_CR12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s11239-006-4968-z","volume":"21","author":"C Sarawate","year":"2006","unstructured":"Sarawate C, Sikirica MV, Willey VJ, Bullano MF, Hauch O (2006) Monitoring anticoagulation in atrial fibrillation. J Thromb Thrombolysis 21(2):191\u2013198. https:\/\/doi.org\/10.1007\/s11239-006-4968-z","journal-title":"J Thromb Thrombolysis"},{"issue":"10","key":"2928_CR13","doi-asserted-by":"publisher","first-page":"e0164076","DOI":"10.1371\/journal.pone.0164076","volume":"11","author":"S Haas","year":"2016","unstructured":"Haas S, Ten Cate H, Accetta G et al (2016) Quality of vitamin K antagonist control and 1-year outcomes in patients with atrial fibrillation: a global perspective from the GARFIELD-AF Registry. PLoS ONE 11(10):e0164076. https:\/\/doi.org\/10.1371\/journal.pone.0164076","journal-title":"PLoS ONE"},{"key":"2928_CR14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1477-9560-12-14","volume":"12","author":"ES Mearns","year":"2014","unstructured":"Mearns ES, White CM, Kohn CG et al (2014) Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression. Thromb J 12:14. https:\/\/doi.org\/10.1186\/1477-9560-12-14","journal-title":"Thromb J"},{"issue":"1","key":"2928_CR15","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/jth.12041","volume":"11","author":"HA Van Den Ham","year":"2013","unstructured":"Van Den Ham HA, Klungel OH, Leufkens HG, Van Staa TP (2013) The patterns of anticoagulation control and the risk of stroke, bleeding and mortality in patients with non-valvular atrial fibrillation. J Thromb Haemost 11(1):107\u2013115. https:\/\/doi.org\/10.1111\/jth.12041","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2928_CR16","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1177\/1076029617747413","volume":"24","author":"JC Mwita","year":"2018","unstructured":"Mwita JC, Francis JM, Oyekunle AA, Gaenamong M, Goepamang M, Magafu M (2018) Quality of anticoagulation with Warfarin at a Tertiary Hospital in Botswana. Clin Appl Thromb Hemost 24(4):596\u2013601. https:\/\/doi.org\/10.1177\/1076029617747413","journal-title":"Clin Appl Thromb Hemost"},{"key":"2928_CR17","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s12913-015-0890-4","volume":"15","author":"DD Barth","year":"2015","unstructured":"Barth DD, Z\u00fchlke LJ, Joachim A, Hoegger T, Mayosi BM, Engel ME (2015) Effect of distance to health facility on the maintenance of INR therapeutic ranges in rheumatic heart disease patients from Cape Town: no evidence for an association. BMC Health Serv Res 15:219\u2013219. https:\/\/doi.org\/10.1186\/s12913-015-0890-4","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"2928_CR18","doi-asserted-by":"publisher","first-page":"e0227458","DOI":"10.1371\/journal.pone.0227458","volume":"15","author":"JR Semakula","year":"2020","unstructured":"Semakula JR, Mouton JP, Jorgensen A et al (2020) A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. PLoS ONE 15(1):e0227458. https:\/\/doi.org\/10.1371\/journal.pone.0227458","journal-title":"PLoS ONE"},{"issue":"2","key":"2928_CR19","doi-asserted-by":"publisher","first-page":"e000521","DOI":"10.1161\/JAHA.113.000521","volume":"3","author":"JP Piccini","year":"2014","unstructured":"Piccini JP, Hellkamp AS, Lokhnygina Y et al (2014) Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial. J Am Heart Assoc 3(2):e000521. https:\/\/doi.org\/10.1161\/JAHA.113.000521","journal-title":"J Am Heart Assoc"},{"issue":"9745","key":"2928_CR20","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/S0140-6736(10)61194-4","volume":"376","author":"L Wallentin","year":"2010","unstructured":"Wallentin L, Yusuf S, Ezekowitz MD et al (2010) Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 376(9745):975\u2013983. https:\/\/doi.org\/10.1016\/S0140-6736(10)61194-4","journal-title":"Lancet"},{"issue":"22","key":"2928_CR21","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1161\/CIRCULATIONAHA.112.142158","volume":"127","author":"L Wallentin","year":"2013","unstructured":"Wallentin L, Lopes RD, Hanna M et al (2013) Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation 127(22):2166\u20132176. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.112.142158","journal-title":"Circulation"},{"issue":"2","key":"2928_CR22","doi-asserted-by":"publisher","first-page":"e057166","DOI":"10.1136\/bmjopen-2021-057166","volume":"12","author":"JC Mwita","year":"2022","unstructured":"Mwita JC, Damasceno A, Chillo P et al (2022) Vitamin K-dependent anticoagulant use and level of anticoagulation control in sub-Saharan Africa: protocol for a retrospective cohort study. BMJ Open 12(2):e057166. https:\/\/doi.org\/10.1136\/bmjopen-2021-057166","journal-title":"BMJ Open"},{"issue":"20","key":"2928_CR23","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1161\/circulationaha.107.750000","volume":"118","author":"SJ Connolly","year":"2008","unstructured":"Connolly SJ, Pogue J, Eikelboom J et al (2008) Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 118(20):2029\u20132037. https:\/\/doi.org\/10.1161\/circulationaha.107.750000","journal-title":"Circulation"},{"issue":"1","key":"2928_CR24","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.thromres.2008.09.016","volume":"124","author":"CL Morgan","year":"2009","unstructured":"Morgan CL, McEwan P, Tukiendorf A, Robinson PA, Clemens A, Plumb JM (2009) Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thromb Res 124(1):37\u201341. https:\/\/doi.org\/10.1016\/j.thromres.2008.09.016","journal-title":"Thromb Res"},{"issue":"3","key":"2928_CR25","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.001349","volume":"4","author":"DE Singer","year":"2015","unstructured":"Singer DE, Hellkamp AS, Yuan Z et al (2015) Alternative calculations of individual patient time in therapeutic range while taking warfarin: results from the ROCKET AF trial. J Am Heart Assoc 4(3):e001349. https:\/\/doi.org\/10.1161\/JAHA.114.001349","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"2928_CR26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.18772\/26180197.2019.v1n1a4","volume":"1","author":"P Parbhoo","year":"2019","unstructured":"Parbhoo P, Jacobson B (2019) A comparison between TTR and FIR as a measure of the quality of anticoagulation in patients with atrial fibrillation. Wits J Clin Med 1(1):23\u201330","journal-title":"Wits J Clin Med"},{"issue":"3","key":"2928_CR27","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1023\/B:THRO.0000011377.78585.63","volume":"15","author":"L Schmitt","year":"2003","unstructured":"Schmitt L, Speckman J, Ansell J (2003) Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in-therapeutic range. J Thromb Thrombolysis 15(3):213\u2013216. https:\/\/doi.org\/10.1023\/B:THRO.0000011377.78585.63","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"2928_CR28","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12959-022-00416-9","volume":"20","author":"TA Tadesse","year":"2022","unstructured":"Tadesse TA, Tegegne GT, Yadeta D, Chelkaba L, Fenta TG (2022) Anticoagulation control, outcomes, and associated factors in long-term-care patients receiving warfarin in Africa: a systematic review. Thromb J 20(1):58. https:\/\/doi.org\/10.1186\/s12959-022-00416-9","journal-title":"Thromb J"},{"issue":"2","key":"2928_CR29","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11239-006-9022-7","volume":"23","author":"J Ansell","year":"2007","unstructured":"Ansell J, Hollowell J, Pengo V, Martinez-Brotons F, Caro J, Drouet L (2007) Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM). J Thromb Thrombolysis 23(2):83\u201391. https:\/\/doi.org\/10.1007\/s11239-006-9022-7","journal-title":"J Thromb Thrombolysis"},{"issue":"7","key":"2928_CR30","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1001\/archinte.160.7.967","volume":"160","author":"GP Samsa","year":"2000","unstructured":"Samsa GP, Matchar DB, Goldstein LB et al (2000) Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Arch Intern Med 160(7):967\u2013973. https:\/\/doi.org\/10.1001\/archinte.160.7.967","journal-title":"Arch Intern Med"},{"issue":"15","key":"2928_CR31","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1001\/archinte.158.15.1641","volume":"158","author":"E Chiquette","year":"1998","unstructured":"Chiquette E, Amato MG, Bussey HI (1998) Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med 158(15):1641\u20131647. https:\/\/doi.org\/10.1001\/archinte.158.15.1641","journal-title":"Arch Intern Med"},{"issue":"1","key":"2928_CR32","first-page":"16","volume":"14","author":"MA Chamberlain","year":"2001","unstructured":"Chamberlain MA, Sageser NA, Ruiz D (2001) Comparison of anticoagulation clinic patient outcomes with outcomes from traditional care in a family medicine clinic. J Am Board Fam Pract 14(1):16\u201321","journal-title":"J Am Board Fam Pract"},{"issue":"6","key":"2928_CR33","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1161\/CIRCOUTCOMES.109.862763","volume":"2","author":"AJ Rose","year":"2009","unstructured":"Rose AJ, Ozonoff A, Grant RW, Henault LE, Hylek EM (2009) Epidemiology of subtherapeutic anticoagulation in the United States. Circulation 2(6):591\u2013597. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.109.862763","journal-title":"Circulation"}],"updated-by":[{"DOI":"10.1007\/s11239-024-03037-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000}}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-023-02928-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-023-02928-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-023-02928-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T02:03:52Z","timestamp":1727748232000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-023-02928-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,13]]},"references-count":33,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["2928"],"URL":"https:\/\/doi.org\/10.1007\/s11239-023-02928-1","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,13]]},"assertion":[{"value":"18 November 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2024","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11239-024-03037-3","URL":"https:\/\/doi.org\/10.1007\/s11239-024-03037-3","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Botswana's Ministry of Health and Wellness granted ethical approval for the University of Botswana\/Princess Marina as a coordinating centre (HPDME13\/8\/1). The authors also obtained necessary ethical approvals from their respective institutional review boards \u2013 Muhimbili National Hospital, Tanzania (MNH\/TRCU\/Perm\/2021\/012); the University of Cape Town, South Africa (HREC:047\/2021); the University of the Witwatersrand Johannesburg, South Africa(R14\/49); Catholic University of Allied Sciences Bugando, Tanzania (CREC\/445\/2020\/); Federal Medical Centre, Umuahia, Nigeria (FMC\/QEH\/G\/596\/VOL.10\/485); University of Ibadan College of Medicine (UI\/EC\/20\/0349; Korle Bu Teaching Hospital Institutional Review Board ( KBCH\/MD\/G3\/20); the University of Port Harcourt Teaching Hospital (UPTH\/ADM\/90\/5.II\/VOL XI\/959; the University of Nigeria Teaching Hospital, Nigeria (UNTH\/CSA\/329\/VOL.5\/09; Federal Teaching Hospital Gombe, Nigeria (NHREC\/25\/10\/2013); Amino Kano is teaching Hospital Nigeria (AKTH\/MAC\/SUB\/12A\/P-3\/VI\/2989; Les Cliniques Universitaires de Kinshasa (213\/CNES\/BN\/PMMF\/2020); University of Uyo Teaching Hospital; College of Health Sciences, Addis Ababa University, Ethiopia (115\/20\/IM and Faculty of Medicine, University Eduardo Mondlane, Mozambique, the Gambia Government\/MRCG Joint Ethics Committee ( 22803). Written informed consent, however, was waived since the study collected data from existing records and did not engage living human subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}